Rafferty Asset Management LLC Acquires 82,309 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Rafferty Asset Management LLC grew its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 90.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 172,960 shares of the company's stock after purchasing an additional 82,309 shares during the period. Rafferty Asset Management LLC owned about 0.22% of Viridian Therapeutics worth $3,316,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in VRDN. Barclays PLC raised its holdings in shares of Viridian Therapeutics by 113.1% in the third quarter. Barclays PLC now owns 125,397 shares of the company's stock valued at $2,851,000 after purchasing an additional 66,550 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Viridian Therapeutics by 89.1% in the fourth quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock valued at $596,000 after purchasing an additional 14,644 shares during the last quarter. Moody Aldrich Partners LLC acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at approximately $1,125,000. R Squared Ltd acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at approximately $26,000. Finally, Rhumbline Advisers raised its holdings in shares of Viridian Therapeutics by 13.1% in the fourth quarter. Rhumbline Advisers now owns 99,938 shares of the company's stock valued at $1,916,000 after purchasing an additional 11,594 shares during the last quarter.

Viridian Therapeutics Stock Performance

VRDN stock traded down $0.10 during midday trading on Friday, reaching $13.57. 645,430 shares of the company were exchanged, compared to its average volume of 1,192,233. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The business has a 50-day moving average price of $13.17 and a two-hundred day moving average price of $16.81. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $27.20. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -3.15 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. The firm's revenue for the quarter was up .0% on a year-over-year basis. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on VRDN shares. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. JMP Securities lowered their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Royal Bank of Canada lowered their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group lowered their target price on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Needham & Company LLC restated a "buy" rating and set a $36.00 target price on shares of Viridian Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $36.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.